How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
You may also be interested in...
Daily notebook from the J.P. Morgan Healthcare Conference: Novo makes its debut appearance and welcomes newcomers to the obesity market; Novartis weighs its options in obesity; Lilly expects donanemab to launch into a primed Alzheimer's market – and it continues to look for more large-market opportunities; and Apellis sees strong 2023 Syfovre sales.
CMS will cover Leqembi now that the US FDA has converted Leqembi’s accelerated approval to traditional approval, giving most patients eligible for treatment access to the drug. Updated labeling puts greater emphasis on safety concerns.
Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond.